NEW YORK (GenomeWeb News) – Pacific Edge today announced it has signed on payor America's Choice Provider Network, expanding access to its bladder cancer test.
ACPN's clients include contracted insurance carriers, third-party administrators, health and welfare funds, employer groups, and self-insured health plans. According to Pacific Edge, 14 million patients in ACPN's network now will have access to its Cxbladder test.
The test is urine-based and comprises five biomarkers. It identifies patients with changes in gene expression and helps rule out cancer in patients with normal gene expression. It will be run out of the CLIA-certified laboratory of Pacific Edge's US subsidiary, Pacific Edge Diagnostics USA, in Hershey, Pa.
Financial and other terms of the agreement with ACPN were not disclosed.
Today's deal follows a recent agreement between the New Zealand-based cancer diagnostics company and preferred provider organization FedMed.